Washington University School of Medicine

Digital Commons@Becker
2020-Current year OA Pubs

Open Access Publications

1-6-2022

Constitutively active SARM1 variants that induce neuropathy are
enriched in ALS patients
A Joseph Bloom
Washington University School of Medicine in St. Louis

Xianrong Mao
Washington University School of Medicine in St. Louis

Amy Strickland
Washington University School of Medicine in St. Louis

Yo Sasaki
Washington University School of Medicine in St. Louis

Jeffrey Milbrandt
Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/oa_4
Part of the Medicine and Health Sciences Commons

Recommended Citation
Bloom, A Joseph; Mao, Xianrong; Strickland, Amy; Sasaki, Yo; Milbrandt, Jeffrey; and DiAntonio, Aaron,
"Constitutively active SARM1 variants that induce neuropathy are enriched in ALS patients." Molecular
Neurodegeneration. 17, 1. 1 (2022).
https://digitalcommons.wustl.edu/oa_4/476

This Open Access Publication is brought to you for free and open access by the Open Access Publications at
Digital Commons@Becker. It has been accepted for inclusion in 2020-Current year OA Pubs by an authorized
administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

Authors
A Joseph Bloom, Xianrong Mao, Amy Strickland, Yo Sasaki, Jeffrey Milbrandt, and Aaron DiAntonio

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/oa_4/476

Bloom et al. Molecular Neurodegeneration
https://doi.org/10.1186/s13024-021-00511-x

(2022) 17:1

RESEARCH ARTICLE

Open Access

Constitutively active SARM1 variants that
induce neuropathy are enriched in ALS
patients
A. Joseph Bloom1* , Xianrong Mao1, Amy Strickland1, Yo Sasaki1, Jeffrey Milbrandt1* and Aaron DiAntonio2*

Abstract
Background: In response to injury, neurons activate a program of organized axon self-destruction initiated by the
NAD+ hydrolase, SARM1. In healthy neurons SARM1 is autoinhibited, but single amino acid changes can abolish
autoinhibition leading to constitutively active SARM1 enzymes that promote degeneration when expressed in
cultured neurons.
Methods: To investigate whether naturally occurring human variants might disrupt SARM1 autoinhibition and
potentially contribute to risk for neurodegenerative disease, we assayed the enzymatic activity of all 42 rare SARM1
alleles identified among 8507 amyotrophic lateral sclerosis (ALS) patients and 9671 controls. We then intrathecally
injected mice with virus expressing SARM1 constructs to test the capacity of an ALS-associated constitutively active
SARM1 variant to promote neurodegeneration in vivo.
Results: Twelve out of 42 SARM1 missense variants or small in-frame deletions assayed exhibit constitutive NADase
activity, including more than half of those that are unique to the ALS patients or that occur in multiple patients.
There is a > 5-fold enrichment of constitutively active variants among patients compared to controls. Expression of
constitutively active ALS-associated SARM1 alleles in cultured dorsal root ganglion (DRG) neurons is prodegenerative and cytotoxic. Intrathecal injection of an AAV expressing the common SARM1 reference allele is
innocuous to mice, but a construct harboring SARM1V184G, the constitutively active variant found most frequently
among the ALS patients, causes axon loss, motor dysfunction, and sustained neuroinflammation.
Conclusions: These results implicate rare hypermorphic SARM1 alleles as candidate genetic risk factors for ALS and
other neurodegenerative conditions.
Keywords: ALS, SARM1, Neurodegeneration, Axon, NAD, Human genetics, Neuropathy
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Background
In recent decades, genetic studies have become a
principle tool for discovering the molecular pathogenesis
underlying neurodegenerative disease. Such investigations have proved especially fruitful for amyotrophic lateral sclerosis (ALS), a rare and devastating motor
neuropathy currently linked to over two dozen distinct
genetic causes that together explain ~ 10% of ALS cases
[1]. As with other diseases, discovery of ALS genes was
facilitated by technological innovations enabling successively more powerful methods, from family-based linkage studies to genome-wide association studies, and
more recently, large exome-sequencing efforts using sophisticated statistical techniques in large case-control
groups [2–4]. However, power to detect such associations is naturally attenuated for genes harboring low
penetrance variants that contribute to risk without necessarily causing disease, which is particularly relevant
given the oligogenic nature of sporadic ALS [5]. This difficulty is compounded when the functional consequences of rare variants cannot be predicted from
sequence alone i.e. for genes where protein-truncating
alleles are not assumed to be pathogenic [3], and all the
more so when variants in the same gene may confer either increased disease risk or protection. In such cases,
the power to detect significant associations can only be
improved by systematically characterizing all the functional variants in a candidate gene [6]. Here we take
such a hypothesis-driven approach to identify potentially
pathogenic alleles of SARM1, a key driver of axon
degeneration.
Trauma and disease in the nervous system activate an
intrinsic axon self-destruction pathway, also known as
Wallerian degeneration, which facilitates the orderly
clearance of damaged axon segments. This choice between maintaining or actively dismantling axons is primarily determined by the action of SARM1, a TIRcontaining NAD+ hydrolase that cleaves NAD+ to generate nicotinamide and cyclic ADPR (cADPR), a useful
biomarker of SARM1 activity [7]. In healthy neurons,
SARM1 is maintained in an autoinhibited state, but injury- or disease-induced depletion of the axon survival
factor NMNAT2 activates SARM1 leading to a stereotyped sequence of events beginning with rapid loss of
NAD+, followed by loss of ATP, defects in mitochondrial
movement and depolarization, influx of calcium,
externalization of phosphatidylserine, and ultimately
axon fragmentation [8, 9]. Sarm1 knockout mice are viable and without apparent phenotypes under routine
conditions, but are protected against neurodegeneration
in models of axotomy, traumatic brain injury, peripheral
neuropathy, glaucoma, and retinal degenerative diseases
[10–18]. Conversely, mutations that decrease NMNAT2
activity lead to polyneuropathy in both humans and
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model organisms [19, 20], suggesting that aberrant
SARM1 activation has a role in human disease. Furthermore, the recent observation that single point mutations
in SARM1 can disrupt enzyme autoinhibition [21–25]
led us to speculate that naturally-occurring human variants might similarly dysregulate SARM1 and thereby increase disease risk. ALS was an attractive candidate
disease because genetic data from multiple large ALS
case-control studies are publicly-available. Notably, polymorphisms in the SARM1 locus have been repeatedly
identified by large GWAS of ALS, though the findings
were largely discounted due to lack of non-synonymous
variants in high linkage disequilibrium and eQTL-effects
upon an adjacent gene, POLDIP226,27. ALS also warrants
particular attention because peripheral axon degeneration accompanies and may precede motoneuron death
during ALS progression [26, 27].
To investigate whether SARM1 mutations that disrupt
the enzyme’s autoinhibition are associated with neurogenerative disorders, we sought to identify rare prodegenerative SARM1 missense variants by biochemically
analyzing every rare SARM1 variant identified in patients
and controls from multiple ALS databases. Provocatively,
the majority of our strongest candidate variants disrupt
SARM1 regulation and confer constitutive activity
in vitro. Furthermore, we demonstrate that the enrichment of rare variants found in ALS patients is driven in
large part by an enrichment of experimentally-confirmed
constitutively active variants. Finally, expression of a
constitutively-active SARM1 allele found in three unrelated patients causes an ALS-like phenotype—motor
dysfunction, cell death, axon loss and sustained neuroinflammation—when expressed in the mouse spinal cord
via intrathecal delivery. We therefore propose that
hypermorphic SARM1 mutations are a congenital risk
factor for ALS. Because the pathogenic effects of SARM1
activity are not limited to motoneurons, we also
hypothesize that rare SARM1 variation may raise risk for
other neurodegenerative conditions such as peripheral
neuropathies. While this manuscript was under review
for publication, a complementary study using different
methods also identified constitutive activity in several of
the same ALS-associated rare SARM1 variants reported
here [28].

Materials and methods
ALS consortia databases

This study is based on anonymized publicly available
human genetic data not associated with demographic
or clinical information beyond ALS case status. All
assayed SARM1 polymorphisms were reported in one
of three databases, accessed January 2020: Project
MinE (http://databrowser.projectmine.com), the University of Massachusetts Medical School Sporadic ALS
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Variant Server (h ttp://als.umassmed. edu/index.
php#SALSbrowser), and the ALS Knowledge Portal
(http://alskp.org).

centrifuged (13,000 g, 10 min, 4 °C), and 10 μl of clear
supernatant was analyzed. NAD+ and cADPR were measured using LC-MS/MS as previously described [33].

Mice

AAV constructs and virus injections

Male and female WT and Sarm1 knockout C57BL/6
mice were housed and used under the direction of institutional animal study guidelines at Washington University in St. Louis. The inverted screen test of strength and
measurement of grip strength were performed as previously described [29, 30]. All protocols received institutional IACUC approval.

AAV particles with a mixture of Php.s and Php.eB capsids [34], containing a human SARM1 gene construct
fused to EGFP, under the control of the human synapsin
promoter, were produced by the Viral Vector Core of
the Hope Center for Neurological Disorders at Washington University in St. Louis. Viral particles were purified
by iodixanol gradient ultracentrifugation and virus titers
were measured by dot blot. Under light anesthesia with
Avertin, 6 × 1011 viral genomes were injected intrathecally at L6/S1. Viral expression in mice 12-weeks post
injection was confirmed by detecting EGFP expression
via immunohistochemical analysis of sectioned DRGs.

DRG culture

Mouse DRG culture was performed as previously described [31]. DRG were dissected from embryonic day
13.5 Sarm1 knockout C57BL/6 or CD1 mouse embryos
and cells suspended in growth medium at a concentration of ~ 7 × 106 cells/ml in 96- well tissue culture plates
(Corning) coated with poly-d-Lysine (0.1 mg/ml; Sigma)
and laminin (3 μg/ml; Invitrogen). Lentiviral particles
containing SARM1 variants and EGFP were generated as
previously described [31]. Lentivirus was added (1–10 ×
103 pfu) after 1–2 days (DIV) and metabolites were extracted or assays were performed at 6–7 DIV. Cell death
was quantified by assaying mitochondrial function
(MTT assay), as previously described [32].
Automated quantification of Annexin V staining

To quantify Annexin V staining, the Alexa Fluor™ 568
conjugate (ThermoFisher) was added to the cultured
neurons at a 1:100 dilution four days after viral infection.
Bright field and fluorescent images were acquired one
hour later using Operetta. Unbiassed image analysis was
performed using ImageJ as follows: total axon area was
measured from the binary bright field images after subtracting background. For Annexin fluorescent intensity
measurement, the fluorescent images were background
subtracted and then Annexin positive area was defined
using the particle analyzer. Data was reported as the
total fluorescent intensity of the Annexin positive area
divided by the axon area.
DRG metabolite extraction and metabolite measurement

At DIV6, tissue culture plates were placed on ice and
culture medium replaced with ice-cold saline (0.9% NaCl
in water, 500 μl per well). Saline was removed and replaced with 160 μl ice cold 50% MeOH in water. Solution was transferred to tubes containing 50 μl
chloroform on ice, shaken vigorously, and centrifuged at
20,000 g for 15 min at 4 °C. The clear aqueous phase
(140 μl) was transferred into microfuge tubes and lyophilized under vacuum. Lyophilized samples were reconstituted with 5 mM ammonium formate (15 μl),

Immunohistochemistry, imaging and quantification

After perfusion with PBS followed by 4% PFA in PBS,
tissues were fixed in 4% PFA in PBS for 1 h at room
temperature and placed in 30% sucrose in PBS overnight
at 4 °C, then embedded in OCT (Tissue-Tek), frozen on
dry ice, and stored at − 80 °C. Longitudinal sections of
6 μm or cross-sections of 20 μm were obtained using a
cryostat and slides were stored at − 20 °C. DRG and
nerve slides were post-fixed in cold acetone, then
washed with PBS. Spinal cord slides were simply washed
three times in PBS. All slides were subsequently blocked
with 4% BSA and 1% Triton X-100 in PBS and incubated
with rat anti-CD68 (1:500; Bio-Rad) and mouse-antiGFP conjugated to Alexa Fluor 488 (1:250; Thermo
Fisher Scientific) overnight in the blocking buffer. Slides
were then washed, incubated in secondary antibodies
(Jackson ImmunoResearch Laboratories), washed, and
mounted in Vectashield with DAPI. Slides were imaged
using a DMI 4000B confocal microscope (Leica Microsystems) with a 20× oil objective and DFC 7000-T camera (Leica Microsystems). For quantification, at least
four images were measured per animal. CD68-positive
cells were counted by a researcher blinded to the images’
treatment group. The total CD68-stained area and nerve
area in each image was quantified with the particle
analyzer in ImageJ using a uniform threshold.
TUNEL apoptosis detection

TUNEL was performed as previously described [35].
Slides prepared for immunohistochemistry were thawed
then postfixed with 4% PFA for 10 min at room
temperature, washed thoroughly with PBS, incubated
with 10 μg/ml proteinase K for 15 min at 37 °C, then
washed with PBS. A positive control slide was incubated
in DNase I (1 U/ml) for 1 h at RT, then washed with
PBS. Slides were then pretreated with TdT buffer (25
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mm Tris-HCl, 200 mm sodium cacodylate, 0.25 mg/ml
BSA, 1 mm cobalt chloride, Roche Diagnostics) at RT
for 10 min. To perform end-labeling, TdT buffer was
combined with terminal deoxynucleotidyl transferase
(Roche Diagnostics, 400 U/slide) and Biotin-16-dUTP
(Roche Diagnostics, 4 μm) and added to slides for 1 h at
37 °C. Slides were thoroughly washed with PBS, then
blocked for 30 min with 5% normal goat serum in PBS
with 0.3% Triton-X, then incubated with Alexa-Fluorconjugated streptavidin (Jackson ImmunoResearch Laboratories) for 30 min at 37 °C. Slides were washed and
mounted in Vectashield with DAPI.
Toluidine blue staining and axon quantification

Sural, sciatic and tibial nerves were fixed in 3% glutaraldehyde in 0.1 M PBS, processed and imaged as previously described [13]. Micrographs were stitched using
Leica software and axons were counted using ImageJ. To
determine axon size distribution and G ratios of the sciatic nerve, four nonoverlapping areas per cross section
were imaged with a 100× oil objective of a Zeiss Axioskop and photographed with a Hitachi camera. Photographs were analyzed using a previously described
binary imaging analysis method [36].
Statistical analysis

The frequency of constitutively active SARM1 variants in
ALS cases vs. controls was compared using Fisher’s
Exact test. All other comparisons (metabolite measurements, axon density and size, g-ratio, MTT assay,
Annexin-V staining, inverted screen test, grip strength,
CD68 staining) were made using two-tailed t-tests. All
statistics were calculated using the R software package.
All data is available upon request.

Results
Enrichment of rare SARM1 variants in ALS patients

The discovery of single point mutations in SARM1 that
confer constitutive NADase activity leading to degeneration
of cultured neurons [10, 22, 23, 37] prompted us to postulate that rare human gain-of-function SARM1 variants
might increase risk for neurodegenerative disease. ALS was
of particular interest because of the large-scale axon loss
that occurs over the course of the disease [26, 27]. To explore this hypothesis, we chose to investigate SARM1 variants found in ALS patients, a population where an
abundance of whole exome and genome data is available.
We identified a total of 30 rare SARM1 coding variants
(missense and small in-frame deletions with allele frequencies < 0.01% in all gnomAD populations [38]) occurring exclusively in ALS patients, culled from three
large publicly-accessible ALS consortia databases that include 8507 cases in total as of January 202041–43
(Table 1). All subjects harboring rare SARM1 variants
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are heterozygotes. Despite being extremely rare, eight of
these variants were each found in two or three ALS patients. We further identified twelve rare SARM1 coding
variants that occur in control individuals from these databases. Altogether, rare variants occur 45 times in 8507
ALS cases and 15 times in 9671 controls (Table 1),
representing a 3.4-fold enrichment of rare SARM1 variants in ALS patients.
SARM1 variants found in ALS patients exhibit constitutive
NAD+ hydrolase activity

To investigate whether the rare SARM1 variants in ALS
patients disrupt autoinhibition, we assayed the NAD+
hydrolase activities of the mutant enzymes encoded by
these variants. We prioritized the variants and first
tested a) those identified in multiple ALS patients but
not in healthy controls and b) those unique to ALS patients (i.e. not reported in any prior human study as of
January 2020). These 15 SARM1 variants (Fig. 1A, Table
1) account for 51% (20/39) of rare SARM1 variants in
ALS patients genotyped in the three large ALS databases
we investigated. To examine the properties of these mutants, we tested them in Sarm1−/− mouse dorsal root
ganglion DRG neurons. We prepared lentiviruses for the
15 SARM1 mutant constructs, infected Sarm1−/− neurons, and assessed their NAD+ hydrolase activity. As validated in our prior publication [21], the ratio of the
SARM1-specific biomarker cADPR [33] over its parent
metabolite NAD+ is the best measure of relative SARM1
activity because cADPR production is specific to
SARM1, while NAD+ concentration is affected by other
cellular processes. Moreover, because NAD+ is the limiting substrate, the ratio of the two molecules accounts
for both SARM1 enzymatic activity and substrate depletion. Measuring cADPR/NAD+, eight of these variants
were determined to be constitutively active, i.e. their
baseline levels of NAD+ were significantly decreased and
levels of cADPR and the ratio of cADPR/NAD+ were
significantly increased in neurons expressing these mutant constructs (Fig. 1). Tellingly, all but one of these
constitutively active variants reside in the autoinhibitory
ARM domain. By contrast, SARM1P332Q, the only relatively common variant found in any gnomAD population
(1.1% in Europeans) is not constitutively active (Fig. 1).
We confirmed that the measured differences in NAD+
hydrolase activity were not due to differences in construct expression levels using expression of the EGFP
also included in the construct (Additional Files 1 and 2).
Indeed, the strongest constitutively active mutant constructs were also associated with the weakest EGFP expression (Fig. 1 and Additional Files 1 and 2), a
phenomenon we and others observe routinely [28],
which we attribute to reduced protein translation due to
NAD+ depletion in the infected cells. Thus, we are likely

(2022) 17:1

Bloom et al. Molecular Neurodegeneration

Page 5 of 15

Table 1 Rare SARM1 missense variants and in-frame deletions found in ALS patients
Variant

rsID

Percent Minor Allele Frequencya

Number of occurrences

African

East Asian

Europeanb

ALS patients

Controls

0

0

0.01

2d

0

0

0

0

1d

0

0.007

0.006

0

3e

0

e

Constitutively active
Δ226–232

rs782325355

Δ249–252
V184G
G206S

rs71373646
rs1555585199

L223P

0

0

0

2

0

0

0

0

1d

0

R267W

rs11652384

0

0

0.001

1e

0

V331E

rs1555585331

0

0

0

1d

0

E340K

rs781854217

0

0

0.003

1d

0

0

0

0

0

1d

C482Y

0

0

0

1d

0

T502P

rs782421919

0

0

0.006

2d,f

0

E693D

rs782331635

0

0

0.005

0

2f

V112I

rs1032963037

0

0

0c

1d

0

A240E

rs1449836804

0

0

0.004

1d

0

0

0

0

1d

0

T385A

Not constitutively active

R244S
A250T

rs1555585243

0

0.06

0

1d

0

A275V

rs376587698

0

0

0.006

1d

0

R310H

rs369186722

0

0

0.01

1d

0

d

0

A341V

rs373458416

0

0

0.01

2

R403P

rs782706244

0

0

0.0009

1f

0

0

0

0

0

1d

0

0

0.001

1d

0

0

0

0

1d

0

0

0

0.001

0

1f

Y429F
E431G

rs1555585662

R465T
N478S

rs1555585804

D483E

rs377210302

0

0

0.002

0

1f

R484C

rs1555585809

0

0

0.0009

1d

0

d

0

A488E

rs782228906

0.004

0

0.02

2

V518L

rs782106973

0

0

0c

3d

0

0

0

0

0

1d
0

S558N
R569C

rs571724138

0

0

0.005

1d

R570Q

rs539229444

0

0.008

0.005

1e

0

I593T

rs782196205

0

0.005

0.002

0

1f

E604K

rs782398426

0.02

0.01

0.005

0

1f

M612V

rs782321764

0

0

0.004

0

2f

0.004

f

1d

d

0

R615H

rs782753946

0.008

0

2

D637Y

rs1451417529

0

0

0

1

A646S

rs782676389

0

0

0.0008

1d

0

V654M

rs782225125

0

0

0.002

0

2f

M672V

rs782774927

0

0

0.004

2e,f

0

S684F

rs782256561

0.004

0

0.004

1f

0

R697C

rs372946020

0.004

0

0.003

3f

1f

R702C

rs781850558

0

0.005

0.002

1f

0

a

gnomAD v2
b
non-Finnish
c
V518L = 0.009% and V112I = 0.001% in gnomAD v3 non-Finnish Europeans
d
MinE [37]
e
ALS Variant Server [39]
f
ALS Knowledge Portal [38]
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underestimating the relative activity of constitutively active alleles. We also saw similar activity when mutant
SARM1 constructs were expressed in wildtype mouse
DRG neurons (i.e. in the presence of endogenous wildtype SARM1) (Additional File 3).
Encouraged by these results, we assayed the activities
of an additional 15 rare missense variants. These were
considered poorer candidates because each is observed
in only a single ALS patient and they are not unique to
the patients as they are also found in the gnomAD database. Among these, we identified two additional constitutively active variants (Table 1). In total, 40% (4/10) of
the SARM1 variants with constitutive NAD+ hydrolase
activity occur in multiple ALS patients.
Enrichment of constitutively-active SARM1 variants in ALS
patients

In order to determine whether constitutively active
SARM1 variants occur significantly more frequently
among ALS patients, we further assayed the activities of
all twelve rare SARM1 missense variants reported among
9671 healthy control individuals included in the large
publicly-accessible ALS consortia databases (Table 1).
Among these, two variants (one of which occurred
twice) demonstrated significantly greater enzymatic activity than the reference allele of SARM1, although notably they are the weakest variants that we define as
constitutively active (see cADPR/NAD+ ratio in Fig. 1).
In total, 3 of 9671 controls versus 15 of 8507 cases carry
a constitutively active SARM1 variant, representing a significant 5.7-fold enrichment among cases (Fisher’s Exact
p = 0.0032).
Constitutively active SARM1 variants found in ALS
patients promote degeneration of cultured neurons

The structure of SARM1 in its autoinhibited state, as determined by cryo-EM, indicates the protein exists as a
compact octamer with its TIR NADase domains isolated
from one another, preventing the TIR oligomerization
necessary for enzymatic activation. Mutational analyses
identified five distinct and non-redundant interfaces required for autoinhibition that support both intramolecular and intermolecular interactions [24]. Point mutants
that disrupt any of these interfaces result in dysregulation of SARM1 activity and this constitutive SARM1 activity promotes the degeneration of cultured neurons
[10, 22, 23, 37]. As in those prior studies, we also recognized changes in cell morphology consistent with cell
death in Sarm1−/− mouse DRG neurons expressing constitutively active variants and chose to quantify cell death
and degeneration for two of the variants, SARM1V184G
and SARM1Δ226–232. These two variants were chosen to
assay because they occurred in three and two independent ALS patients respectively (Table 1). The mutant
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enzymes were expressed in Sarm1−/− DRG neurons and
degeneration was measured by two methods.
Fluorescently-labeled Annexin V, which binds to phosphatidylserine, was used to determine whether the expression of either variant construct significantly
compromises axon health. Annexin V binding is a useful
proxy for axon health as neurites undergoing Wallerian
degeneration expose phosphatidylserine on their extracellular surfaces similarly to apoptotic cells [9, 40].
Neuronal death was quantified using an oxidoreductase
activity assay, a common measure of cell viability. Both
assays demonstrated that both ALS-associated SARM1
variants produced a significant degenerative effect relative to the common reference allele (Fig. 2).
While these variants exhibit constitutive NAD+ hydrolase activity, it is formally possible that they mediate
their pro-degenerative effects via a distinct toxic mechanism. To investigate this alternate hypothesis, we generated constructs containing two mutations, either of
the ALS-associated variants, i.e. SARM1V184G or
SARM1Δ226–232, together with E642A, a point mutation
in the TIR domain that disrupts the catalytic glutamate
required for SARM1 NAD+ hydrolase activity and axon
degeneration [23, 41–44]. In both cases, introducing
E642A abolishes enzymatic activity and the detrimental
effects of the constructs on cell body and axon health
(Fig. 2). Hence, these ALS patient-derived SARM1 variants promote degeneration via loss of autoinhibition and
resulting constitutive NAD+ hydrolase activity.
The ALS-associated SARM1V184G variant induces motor
impairment, peripheral axon loss and neuroinflammation
in mice

To test whether rare ALS-associated SARM1 variants
can promote neurodegeneration in vivo, AAV viral vectors were administered intrathecally to male and female
six-week old wild-type mice, expressing either the common human allele of SARM1 (the reference allele) or
SARM1V184G. V184G was chosen to examine in vivo because it was the rare variant that occurred most frequently among ALS patients, found in three
independent subjects. In these constructs, each SARM1
protein was fused to EGFP and expressed under the control of the human synapsin promoter. AAV viruses were
produced using a mixture of PHP. S and PHP.eB serotype capsids (both derived from AAV9 [34]) in order to
infect neurons in the spinal cord and DRGs.
Animals injected with AAV expressing the common
SARM1 allele had no discernible behavioral phenotypes.
By contrast, those injected with AAV-SARM1V184G exhibited motor impairment. Two of the mice rapidly progressed to full limb paralysis 3–4 days after injection.
Other animals injected with SARM1V184G (7/9) displayed
less dramatic motor deficits characterized by significant
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(See figure on previous page.)
Fig. 1 Identification of dysregulated SARM1 variants found in ALS patients. (A) Schematic representation of the domain structure of SARM1
marked with every rare variant found in ALS patients. Constitutively-active variants are indicated above in red. Bold variants were prioritized
because they were identified in multiple ALS patients or were unique to ALS patients. Δ indicates an in-frame deletion. MLS, mitochondrial
localization signal; ARM, HEAT/Armadillo motif; SAM, sterile alpha motif; TIR, Toll/interleukin-1 receptor homology domain. (B) The ratio of cADPR/
NAD+, cADPR, and NAD+ levels from cultured Sarm1−/− DRG neurons infected with human SARM1 constructs carrying every rare variants
identified in multiple ALS patients or unique to ALS patients (red), every rare variant found in controls (green), and the most common SARM1
variant, P332Q (gray), relative to the common reference human genome allele of SARM1 (black). *p < 0.05; **p < 0.0005 difference from reference
allele. We demonstrate that strongly constitutively active variants predominate among those SARM1 variants identified in multiple ALS patients or
unique to ALS patients, while the only two significantly active variants discovered in controls are comparatively weak

muscle weakness as measured by the inverted screen
assay (Fig. 3) or hindlimb grip strength (Additional File 4).
These deficits were detected within 3 weeks of injection
and did not progress significantly during the 12-week
observation period.
To characterize the neurodegeneration caused by
SARMV184G expression, the intrathecally injected mice
were examined for evidence of axon degeneration and
neuron loss. We examined the two mice that became
rapidly paralyzed and the other mice with less severe
disease as separate cohorts because of the difference in
phenotype. Unfortunately, because we do not see EGFP
expression with any construct until at least a week post-

infection, we were unable to use EGFP to confirm expression in mice sacrificed early. In the spinal cords of
the paralyzed mice, there was clear evidence of cell death
around the ependymal canal as detected by TUNEL
staining (Fig. 4, Additional File 5). Neuroinflammation
was observed throughout the spinal cord of these mice
as evidenced by prevalent staining for CD68, a marker of
activated macrophages (Fig. 4). Neither of these phenotypes were observed in animals injected with the common SARM1 allele construct (Fig. 4). In this cohort,
levels of CD68 staining in sciatic nerves did not differ
between mice injected with SARM1V184G and the control
SARM1 AAV (Additional File 5), nor did any of the mice

Fig. 2 Neurodegeneration in cultured neurons transfected with ALS-associated SARM1 variants. (A) Neuron death as measured by the MTT assay
and (B) axon degeneration as measured by Annexin V staining in Sarm1−/− DRG neurons infected with lentivirus expressing SARM1 variant
constructs as well as double mutant constructs including E642A, a point mutation that disrupts SARM1 NAD+ hydrolase activity, relative to the
common SARM1 reference allele. All data are expressed as the percent of surviving cells or area of Annexin stained axons relative to neurons
infected with the reference allele. (C) Representative bright-field and Annexin V-stained images of axons from Sarm1−/− DRG cultures infected
with variant and SARM1 reference allele constructs. *p < 0.005 difference from reference allele. These results demonstrate that constitutive SARM1
activity causes cell death and axon degeneration while expression of control SARM1 does not
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Fig. 3 Motor dysfunction in mice injected intrathecally with a
SARM1V184G AAV construct. Average time suspended from an
inverted screen (maximum 120 s) for C57BL/6 mice injected with a
human SARM1 reference allele (n = 8) or SARM1V184G (n = 7) AAV
compared to uninjected controls (n = 3) 3, 9 and 12 weeks postinjection. *p < 0.005 difference from both the reference allele and
uninjected controls. These results demonstrate that infection with
SARM1V184G causes persistent motor dysfunction while the control
SARM1 construct does not

display significant myelin defects or vacuolization in the
sural, sciatic or tibial nerves 3–4 days post-infection
(data not shown).
The mice treated with SARM1V184G that displayed a
less severe behavioral response were sacrificed twelve
weeks post-injection. Expression of viral constructs in
these mice was confirmed using the presence of EGFP in
the DRGs and were similar for each construct (Additional Files 6 and 7). Pathological inspection of their
spinal cords revealed no evidence of ongoing apoptosis
or elevated CD68 staining (Fig. 5). Their peripheral
nerves, however, contain almost 10-fold more CD68positive macrophages than those treated with the control
SARM1 allele (Fig. 5). Macrophages increase in size
upon activation [45], and the SARM1V184G-infected mice
also have a 1.6-fold greater CD68-stained area per cell
than do control mice, yielding a 15.2-fold difference in
total CD68-stained area. Hence, neuronal expression of
SARM1V184G triggers an elevated inflammatory response
in peripheral nerves that persists for at least twelve
weeks after treatment [46].
The average fiber densities in the peripheral nerves of
the SARM1V184G-injected mice are also lower than those
injected with AAV expressing the common human allele, demonstrating that expression of the constitutively

Page 9 of 15

active SARM1 promotes axon loss. The number of axons
were counted in the sural, sciatic and tibial nerves. In
both the sural and sciatic nerves, the density of axons is
significantly lower (p < 0.001), a trend that is evident in
the tibial nerve but that did not reach statistical significance (Fig. 5). The average axon size and extent of myelination (g-ratio) does not differ significantly between
the variant and common SARM1 allele treated animals
(Fig. 5, p > 0.1, n = 16). Myelin defects and vacuolization
are not observed in these nerves, indicating a lack of ongoing axon loss. The lack of axon defects at twelve
weeks is consistent with the early, but stable, deficits in
motor function observed in mice receiving the
SARM1V184G virus (Fig. 3). We interpret these data as
evidence that a subset of neurons—those infected with
virus and sufficiently susceptible to SARM1-dependent
degeneration—lost their axons before three weeks, while
others, including uninfected neurons, remained healthy
and functional up to twelve weeks. Inter-animal differences in motor dysfunction severity likely reflect variability in infection efficiency.

Discussion
SARM1, the chief axon executioner, directs the ordered
elimination of damaged axons, a process called Wallerian degeneration. In healthy axons, this potent NAD+
hydrolase is maintained in an autoinhibited state, waiting
to be activated by injury or disease. SARM1 activation
leads to a rapid loss of NAD+, metabolic catastrophe and
subsequent axon fragmentation [7, 9]. Due to its central
role in programmed axon destruction, prior investigations of SARM1 vis-à-vis disease have focused on inhibiting the pathway to block degeneration downstream of
specific injury and disease processes [10–16]. This is the
first study to address genetically-determined gain-offunction SARM1 activity as a candidate disease mechanism in itself, building upon the discovery of engineered
mutations that disrupt SARM1 autoinhibition and promote neurodegeneration in vitro [21–25]. Provocatively,
we find that many rare SARM1 variants found in ALS
patients also lack normal autoinhibition, and that such
an allele induces neurodegeneration and neuroinflammation when expressed in the mouse nervous system.
A number of prior findings are consistent with the hypothesis that SARM1 activity contributes to pathological
neurodegeneration, particularly in ALS. First, noncoding variants in the SARM1 locus were repeatedly detected in genome-wide association studies of ALS,
though a causal link has been largely discounted [47,
48]. Second, aggregation of TDP-43, a hallmark of most
ALS (excluding SOD1-ALS), results in the reduced expression of STMN2, a key axon survival factor that inhibits SARM1-mediated axon destruction [49–52].
Finally, Sarm1 loss suppresses neurodegenerative
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Fig. 4 Rapid cell death and neuroinflammation in mice injected intrathecally with a SARM1V184G AAV construct. This figure demonstrates
anatomical findings from the small subset of mice with rapid onset pathology. (A) Representative images of spinal cord sections stained with
DAPI and the apoptosis marker TUNEL from mice 2 days after injection with a SARM1V184G or SARM1 human reference allele construct. (B)
Representative images of spinal cord stained with DAPI and the macrophage marker anti-CD68 from mice 2 days after injection with a
SARM1V184G or reference allele construct. These images demonstrate that mice that become paralyzed shortly after injection with SARM1V184G
exhibit cell death and activated macrophages in their spinal cords while mice injected with the control SARM1 construct do not

phenotypes in many injury and disease models [10–18],
including a mouse that expresses pathogenic human
TDP-43 [53]. However, this suppression does have
limits, as Sarm1 deletion does not ameliorate ALS symptoms in the SOD1G93A mouse model [30].
The hypothesis that naturally-occurring SARM1 polymorphisms could disinhibit normal enzyme activity and
predispose to degenerative disease led us to examine exome sequence data from several well-annotated studies
of ALS [39, 54, 55]. We discovered multiple rare SARM1
variants in these patients that result in constitutive activity due to loss of autoinhibition, and consequently promote neuron death and axon degeneration in vitro.
Importantly, a single point-mutation that disrupts
SARM1 catalytic activity is sufficient to negate the prodegenerative effects of these ALS-associated variants,
demonstrating the degenerative phenotype requires
SARM1 NAD+ hydrolase activity and is not due to a

non-specific mechanism such as the toxic aggregation of
a misfolded protein. Expression in the mouse CNS of a
SARM1 construct harboring one such variant causes
motor dysfunction and sustained neuroinflammation,
abnormalities not observed in mice treated with the
common human reference allele of SARM1. The mechanism by which constitutive activity would predispose to
neurodegeneration appears straightforward. Low NAD+
is a death sentence for energy-hungry neurons and is associated with both disease and aging-related functional
defects [56, 57]. Indeed, NAD+ augmentation ameliorated ALS symptoms in a small clinical trial [58]. We
speculate that the contrast between virus-infected mice
that rapidly display severe degenerative phenotypes, and
human ALS patients who are typically diagnosed only
after several decades of life, likely reflects the difference
in SARM1 expression—i.e. viral over-expression precipitates abrupt metabolic catastrophe in this model,
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(See figure on previous page.)
Fig. 5 Persistent neuroinflammation and axon loss in mice injected intrathecally with a SARM1V184G AAV construct. This figure demonstrates
anatomical findings from the larger subset of mice with slower onset pathology. (A) The normalized average number of cells stained by the
macrophage marker anti-CD68 in nerve, and the average percent area of total anti-CD68 staining in nerve and in spinal cord sections, from
C57BL/6 mice injected with a SARM1V184G (n = 7) AAV construct relative to those injected with a human SARM1 reference allele construct (n = 8)
12 weeks post-injection; *p < 10− 4 difference from reference allele. (B) Representative images of sural nerve stained with DAPI and anti-CD68 from
mice 12 weeks after injection with a SARM1V184G or reference allele construct. White arrows indicate CD68-positive activated macrophages. (C)
Representative images of toluidine blue stained sural nerve sections. (D) Average fibers per cross-sectional μm2 in sural, sciatic and tibial nerves
from mice 12 weeks after injection with a SARM1V184G (n = 7 mice) or reference allele construct (n = 8); *p < 0.05, **p < 0.001. (E) Average g-ratio
(ratio between the inner and outer myelin sheath) for axons in the sural, sciatic and tibial nerves from mice 12 weeks after injection with a
SARM1V184G or reference allele construct. These analyses demonstrate that mice injected with SARM1V184G exhibit axon loss and persistent
neuroinflammation in their nerves 12 weeks after infection, compared to mice injected with a control SARM1 construct

whereas chronic suboptimal NAD+ levels lead to gradual
motoneuron attrition in patients. Hence, our studies
demonstrate what activating SARM1 mutations can do
in an animal model, but assessing whether such mutations model ALS will require generation of germline mutations in Sarm1 that mimic the human variants.
Sophisticated statistical methods and next-generation
sequencing have allowed the contribution of rare variation to disease risk to be addressed using techniques
that identify genes containing an excess of presumably
deleterious rare variants among cases relative to healthy
controls [4]. However, because SARM1 is a switch that
may be pushed either ‘off’ or ‘on’, the consequence of
any genetic perturbation defies simple assumptions. Extensive structure/function analysis has shown that single
point mutations in SARM1 can 1) abolish NADase function [41], 2) create a neuroprotective dominant negative
[59], 3) alter the enzyme’s sensitivity to regulation by
NMN and NAD+ [21, 22], or 4) disrupt its autoinhibitory domain leading to pro-degenerative constitutive activity [24]. Indeed, altering a specific residue by
substituting different amino acids at the same position
can confer opposite effects [21], underscoring the futility
of attempting to determine function in silico rather than
experimentally.
Typically, human geneticists discover genotypephenotype associations based on assumptions about the
functional consequences of genetic variation, and laboratory biologists pursue the mechanisms underlying these
associations using relevant experimental systems. But
there are important limitations of this paradigm, including 1) that small and under-studied populations are disadvantaged because findings from the best-powered
association studies (usually of European-ancestry subjects) are inevitably prioritized, 2) genetic diversity can
hamper discovery because associations are most easily
found in homogenous populations where risk is driven
by a few common variants rather than many lessfrequent variants [60–65] and 3) initial association tests
fail to account for the unpredictable consequences of
most human mutations. This is especially true when
protein-truncating variants are not pathogenic, and

when gain-of-function and loss-of-function variants in
the same gene have opposite effects on disease risk [6].
By comprehensively characterizing the functional consequences of all potentially pathogenic variants in a strong
candidate locus, we sought to reverse the usual paradigm
and increase our power to detect an association based
on a strong mechanism-based hypothesis. The result
was to demonstrate a significant enrichment among ALS
patients of a particular class of variants in our candidate
gene—those conferring constitutive SARM1 enzymatic
activity. In addition, with the increasing use of exome sequencing for genetic diagnosis of neurodegenerative disease [66], our specific results provide immediately
clinically relevant information, as well as provide a
methodology for assessing the likely pathogenicity of
further SARM1 variants in patients. Our results regarding naturally-occurring human variants also align closely
with the findings of prior structure-function investigations of SARM1, namely the centrality of the ARM domain in SARM1 autoinhibition [21–25]. All but three of
the constitutively active variants we identified lie in the
ARM domain, and these exceptions are the three weakest constitutively active alleles assayed (Fig. 1). The two
weakest variants were also those found in healthy controls, and we speculate that the quantitative difference
between these and other variants may suggest a threshold between significant differences in in vitro activity
and clinically significant differences in pathogenicity.
While both of these control variants show at least 5-fold
higher basal enzymatic activity than the common reference allele of SARM1 in vitro, the most common ALS
patient-derived variant, V184G, has more than 26-fold
higher activity (Fig. 1). Finally, we also observe that constitutively active variants do not fully account for the enrichment of rare SARM1 variants associated with ALS.
While constitutively-active variants are 5.7-fold enriched,
non-constitutively active rare variants are also 2.8-fold
enriched in ALS patients compared to controls. Notably,
our group has previously probed the allosteric modulation of SARM1 using engineered mutations that alter
SARM1 activation without changing basal activity [21].
We therefore hypothesize that other classes of
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pathogenic SARM1 variants may exist that act via
mechanisms other than directly disrupting enzyme
autoinhibition.
Fortunately, though the number of ways to disrupt
SARM1 may be myriad, for patients harboring deleterious SARM1 polymorphisms the therapeutic solution
could be universal. As we have demonstrated, NAD+
hydrolase activity is required for the prodegenerative
function of SARM1 [41], and that catalytic machinery is
an attractive drug target. Indeed, small molecule SARM1
inhibitors are currently in development [67], and we
have shown that a SARM1 dominant negative gene therapy can potently block SARM1-mediated programmed
axon degeneration in mice [59]. Establishing that
SARM1 inhibition is safe and effective in carriers of
pathogenic SARM1 variants could provide a vital stepping stone toward the use of SARM1-directed therapeutics more generally for ALS and other diseases that
involve axon degeneration.

Conclusions
In summary, we identified 12 constitutively active
SARM1 variants among all 42 rare missense variants reported among 8507 ALS patients and 9671 controls.
These include more than half of those that are unique to
those patients or that occur in multiple patients. We also
demonstrate a > 5-fold enrichment of constitutively active variants among patients compared to controls. Expression of constitutively active ALS-associated SARM1
alleles is pro-degenerative, both in vitro in cultured neurons and in vivo in the mouse central nervous system.
These results implicate rare hypermorphic SARM1 alleles as candidate genetic risk factors for ALS and other
neurodegenerative conditions.
Abbreviations
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Additional file 1. Bright field and matching fluorescent images of
cultured mouse DRG neurons infected with SARM1-EGFP constructs
including the human reference allele, every constitutively active SARM1
variant found in ALS patients and ten rare SARM1 variants found in
controls. The expression of EGFP in neurons infected with ALS-associated
constitutively active SARM1 variants is similar or less than EGFP expression
in reference SARM1-infected neurons (compare background fluorescence
to cell bodies).
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Additional file 2. EGFP fluorescence intensity per cell area in cultured
mouse DRG neurons infected with SARM1-EGFP constructs including
every constitutively active SARM1 variant found in ALS patients and ten
rare SARM1 variants found in controls, normalized to the human
reference SARM1 allele. Reduced EGFP expression in cells infected with
constitutively active SARM1 alleles is likely due to NAD+ depletion by
SARM1 leading to impaired protein translation.
Additional file 3. The ratio of cADPR/NAD+ levels in cultured CD1 wildtype DRG neurons (i.e. expressing endogenous SARM1) infected with human SARM1 constructs carrying rare variants identified in ALS patients.
The variants are significantly more active than the reference human
SARM1 allele in the presence of endogenous SARM1. This activity is
dependent on the activity of the SARM1 mutant, as demonstrated by the
loss of activity when a second activity-abolishing mutation, E642A, is introduced into the construct. Data are expressed relative to cADPR/NAD+
in reference SARM1-expressing neurons.
Additional file 4. Forelimb grip strength in male and female mice 3
weeks after injection with SARM1 AAV constructs.
Additional file 5. Percent area of TUNEL staining in spinal cord, and
percent area of CD68 staining in sciatic nerves, two days after injecting
mice with SARM1 AAV constructs.
Additional file 6. Representative images of dorsal root ganglia from
mice 12 weeks post intrathecal injection with AAV constructs containing
SARM1 or the ALS-associated constitutively active variant SARM1V184G
fused to EGFP, demonstrating similar expression levels from the two
constructs.
Additional file 7. Percent of EGFP positive dorsal root ganglia from
mice intrathecally injected with AAV constructs containing the reference
SARM1 allele or SARM1V184G fused to EGFP.
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